Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

NCT01462773 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Bortezomib
DRUG: Interferon Alfa-2b

Sponsor

Ohio State University Comprehensive Cancer Center